Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521310 | 0.84 | TRPV4 (0.36) | MAOBMAOAGPR35TRPV4MEN1 | |
| SCHEMBL22319431 | 0.80 | MAOB (0.39) | MAOBMAOAGPR35TRPV4MEN1 | |
| SCHEMBL16122644 | 0.76 | TSHR (0.37) | MAOBMAOAGPR35MEN1TTR | |
| SCHEMBL9478745 | 0.76 | XDH (0.37) | MAOBMAOAGPR35 | |
| SCHEMBL16098127 | 0.76 | TRPV4 (0.38) | MAOBMAOAGPR35TRPV4MEN1 | |
| SCHEMBL2040623 | 0.74 | VCAM1 (0.41) | GPR35TRPV4MEN1TTRALB | |
| SCHEMBL28365899 | 0.74 | TDP1 (0.41) | MAOBMAOAGPR35TRPV4MEN1 | |
| SCHEMBL23928094 | 0.74 | MAOB (0.36) | MAOBMAOATRPV4MEN1TTR | |
| SCHEMBL10878012 | 0.74 | MAOA (0.31) | MAOBMAOATRPV4MEN1TTR | |
| SCHEMBL7925140 | 0.73 | TRPV4 (0.36) | TRPV4MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846978-B2 | Electronic devices comprising novel phosphonic acid surface modifiers | IMPERIAL INNOVATIONS LTD. (GB) | 2014-09-30 | — | — | US | disclosed |
| US-20110114935-A1 | Stable electrodes with modified work functions and methods for organic electronic devices | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110114935-A1 | Stable electrodes with modified work functions and methods for organic electronic devices | EPCAM, EMD, L1CAM | MAOB 1623/4885MAOA 1203/4885GPR35 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.